Adaptive Biotechnologies Corp (ADPT) Stock
ADPT has an Alpha Score of 34 out of 100 (poor), computed on Nov 3, 2026 from 2 of 4 sub-scores. 7 of the hedge funds AlphaScala tracks reported ADPT in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Viking Global Investors's at $643.37M. Company insiders reported 0 open-market buys and 58 sales on SEC Form 4 in the 90 days to Nov 3, 2026.
What is ADPT's Alpha Score?
How it works →Alpha Score of 34 reflects weak overall profile with weak momentum, weak quality. Based on 2 of 4 signals – score is capped at 75 until remaining data ingests.
Computed from 2 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.
Computed Nov 3, 2026
A rules-based research rating, not a recommendation to buy or sell.
Which hedge funds own ADPT?
From 13F filings| Fund | Shares Held | Position Value | Change vs prior Q |
|---|---|---|---|
| Viking Global Investors Andreas Halvorsen | 29.99M | $643.37M | n/a |
| D.E. Shaw David Shaw | 4.63M | $99.22M | +135% |
| ARK Invest Cathie Wood | 2.09M | $44.84M | -0% |
| Millennium Management Israel Englander | 505K | $10.83M | -53% |
| Renaissance Technologies Jim Simons (founder) | 303K | $6.50M | +26% |
| Marshall Wace | 292K | $6.27M | +238% |
| Citadel Ken Griffin | 181K | $3.89M | -50% |
13F holdings as of Jun 30, 2026
Explore all tracked funds →Are Adaptive Biotechnologies Corp insiders buying or selling?
SEC Form 4 filings| Date | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| Nov 3, 26 | Rubinstein Julie | President and COO | SELL | 11.9K | $309K |
| Nov 2, 26 | Rubinstein Julie | President and COO | SELL | 9.3K | $235K |
| Nov 2, 26 | Rubinstein Julie | President and COO | SELL | 2.6K | $68K |
| Oct 30, 26 | Rubinstein Julie | President and COO | SELL | 9.5K | $252K |
| Oct 30, 26 | Rubinstein Julie | President and COO | SELL | 2.4K | $66K |
| Oct 29, 26 | Rubinstein Julie | President and COO | SELL | 11.9K | $336K |
| Oct 28, 26 | Rubinstein Julie | President and COO | SELL | 11.7K | $332K |
| Oct 28, 26 | Rubinstein Julie | President and COO | SELL | 200 | $6K |
| Oct 27, 26 | Rubinstein Julie | President and COO | SELL | 3.0K | $80K |
| Oct 27, 26 | Rubinstein Julie | President and COO | SELL | 8.9K | $244K |
SEC Form 4 filings as of Nov 3, 2026
See cluster-buy signals across all tickers →What are ADPT's key statistics?
Key statistics as of Nov 3, 2026
How does ADPT's valuation compare with the Healthcare sector?
| Metric | ADPT | Healthcare median | Companies in median |
|---|---|---|---|
| Net margin | -20.73% | 4.64% | 150 |
| Return on equity | -32.64% | 6.41% | 169 |
Medians over the Healthcare stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.
ADPT price chart
Powered by TradingViewWhat does Adaptive Biotechnologies Corp do?
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company that develops an immune medicine platform for diagnosing and treating various diseases. The company's core offering is its immunosequencing platform, which uses proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data that decodes the adaptive immune system. Its primary diagnostic product is clonoSEQ, a test that detects and monitors minimal residual disease (MRD) in cancer patients by measuring remaining cancer cells during and after treatment. This capability is particularly valuable in hematology-oncology, where it helps optimize patient care and drug development across lymphoid cancers. The company also develops solutions in cellular therapy and vaccines. Headquartered in Seattle, Washington, Adaptive Biotechnologies serves clinical laboratories, pharmaceutical companies, and healthcare providers seeking to leverage immune system insights for improved patient outcomes and precision medicine applications.